BioPharm Intl

Our latest survey of #biopharma professionals on #DigitalTransformation in the industry uncovered a hype-actual adoption gap. Get the full industry report at lnkd.in/eeSbk4ba #AI

Resilient operations start with smart investment—modern manufacturing and supply chain strategies are driving faster delivery, higher quality, and more predictable performance worldwide. #SupplyChain hubs.li/Q04f9QYx0 hubs.li/Q04f9Q0z0

@CREATEMedicines secures $122M Series B to advance in vivo CAR-T for autoimmune disease and oncology. Could this reshape industry R&D strategy? Learn more: hubs.li/Q04gDcGY0 #InVivoCART #AutoimmuneDisease #Oncology #mRNA #LNP #BiotechFunding #CellTherapy #Immunotherapy

Learn how #QSP and mechanistic modeling are transforming #CART and cell/gene therapy development in oncology. Watch @Certara's Dr. Armin Sepp discuss insights from his presentation at @AAPSComms #NBC2026: hubs.li/Q04gpm2Y0 #CellTherapy #MechanisticModeling #Oncology

Unlock complete analytical workflows for GLP-1 therapeutics—ensuring purity, stability, and compliance across development and QC: hubs.li/Q049VGjT0 #Biopharma

@Agilent's Dr. Ganesh Bala discuses how LC-MS-based multi-attribute methods are advancing biotherapeutic and ADC analysis at @AAPSComms #NBCS2026. Watch the full interview: hubs.li/Q04gs6Dl0 #BiopharmaAnalytics #MassSpec #MultiAttributeMethods #Bioconjugates #ADCs

@IsomorphicLabs secures $2.1B to scale its IsoDDE AI drug design engine and expand global partnerships. How will AI-first platforms transform drug discovery? Learn more: hubs.li/Q04grxG00 #AIDrugDiscovery #BioTechNews #AIinHealthcare #DrugDevelopment

A major R&D alliance sees @bmsnews and #HengruiPharma join forces on 13 early-stage oncology, hematology, and immunology programs, with the deal valued up to $15.2 billion. Learn more: hubs.li/Q04gcP5L0 #Oncology #Immunology #PharmaNews #LifeSciences

Explore the latest in precision medicine on #TheBioPharmBrief: FcRn modulation, biomarker-guided therapies, and accelerated ADC pathways are transforming autoimmune and oncology care. Listen to now: hubs.li/Q04g9ZbG0 #PrecisionMedicine #Oncology #ADCs

FDA approves zenocutuzumab-zbco (Bizengri) for adults with advanced NRG1 fusion-positive cholangiocarcinoma, expanding targeted options in rare GI cancers. Learn more: hubs.li/Q04g5_Xl0 #Oncology #FDAApproval #TargetedTherapy #NRG1

@US_FDA extends review of @Eisai_SDGs & @biogen’s once-weekly Leqembi (lecanemab-irmb) to Aug. 24, 2026 with no new concerns. A home-based autoinjector could transform Alzheimer’s care. Learn more: hubs.li/Q04fZBvL0 #Alzheimers #Biotech #DrugDevelopment

Can cell therapy end insulin dependence in type 1 diabetes? Islet cell therapies offer hope for lifelong blood sugar control and improved quality of life, says #SanaBiotecnology CEO Dr. Steve Harr. Learn more: hubs.li/Q04fTSlG0 #CellTherapy #DiabetesInnovation

@GSK and #SiranBio announce a global licensing deal for SA030, an #siRNA therapy targeting ALK7 to address visceral fat and cardiometabolic risk. Get more details: hubs.li/Q04fNzPH0 #CardiometabolicDisease #MetabolicHealth #ObesityTreatment #NASH #ChronicKidneyDisease

#LTZTherapeutics secures $38M, advancing its U-MCE platform and bispecifics for NHL and B-cell malignancies. How will myeloid-engager innovation impact oncology? Learn more: hubs.li/Q04fG41R0 #ImmunoOncology #BiopharmaInnovation #OncologyRAndD #CellEngagers

@ViridianThera's REVEAL-2 phase 3 data show elegrobart delivers rapid, meaningful improvement in chronic thyroid eye disease with just 3 doses. Learn more: hubs.li/Q04fqyq00 #ThyroidEyeDisease #Ophthalmology #ClinicalTrials #BiotechInnovation

Promising results from @TakedaPharma show that TAK-881 matches Hyqvia’s PK with half the infusion volume, offering shorter infusions and fewer visits for PID care. Learn more: hubs.li/Q04fh7Rx0 #Immunology #ClinicalTrials #BiotechInnovation #PatientExperience

@US_FDA fast track for @HealthMrm's MH002 signals a breakthrough in UC, targeting disease biology with live microbiome therapy. How will this reshape IBD innovation? Details: hubs.li/Q04f7NPg0 #UlcerativeColitis #MicrobiomeTherapeutics #DrugDevelopment #ClinicalTrials

Discover how clinical durability, targeted combos, and US manufacturing are shaping global therapy access. Tune in to the latest episode: hubs.li/Q04f48hz0 #OncologyInnovation #BiologicsManufacturing #USBiopharma #TheBioPharmBrief

Explore the future of #biomanufacturing with smart single-use tech, automation, and resilient supply chains, as highlighted at #INTERPHEX2026. Watch the full recap: hubs.li/Q04f3_nT0 @INTERPHEX #BiomanufacturingInnovation #SingleUseTechnology #ContinuousProcessing

Unlock the full article: biopharminternational.com/view/why-does-…

Targeting beyond the liver is one of the biggest hurdles in genetic medicine. So how are researchers solving it? Explore more in the comments 👇 #BioPharm #GeneticMedicines #LNPs